8-K: PROCEPT BioRobotics Reports Strong Q1 2025 Results and Raises Full-Year Revenue Guidance

PROCEPT BioRobotics announced a 55% increase in first-quarter revenue and raised its full-year 2025 revenue guidance to $323 million.

Summary

• PROCEPT BioRobotics Corporation reported its financial results for the first quarter of 2025.
• Total revenue for the quarter was $69.2 million, a 55% increase compared to the same period in 2024.
• U.S. revenue grew by 50% to $60.3 million, driven by system sales and increased handpiece revenue.
• U.S. handpiece and consumable revenue increased by 61% to $38.0 million.
• U.S. system and rental revenue increased by 31% to $18.7 million.
• International revenue saw a significant increase of 104%, reaching $8.9 million.
• The company sold 43 new robotic systems in the U.S. during the quarter.
• Gross margin improved to 64% compared to 56% in the prior year period.
• Operating expenses increased to $71.6 million due to commercial expansion, R&D, and administrative costs.
• Net loss was $24.7 million, an improvement from the $26.0 million loss in the prior year period.
• Adjusted EBITDA loss was $15.8 million, compared to a loss of $20.4 million in the prior year period.
• Cash, cash equivalents, and restricted cash totaled $319.2 million as of March 31, 2025.
• Long-term borrowings totaled $52.0 million.
• The company increased its full-year 2025 revenue guidance to $323 million, representing 44% growth over the prior year.
• Full-year 2025 gross margin is expected to be approximately 64.5%.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, improved gross margins, and increased revenue guidance. While the company is still operating at a loss, the trend is improving, and management expresses confidence in future performance.

Positives

• Significant revenue growth of 55% in Q1 2025.
• Strong growth in U.S. handpiece and consumables revenue (61%).
• Substantial increase in international revenue (104%).
• Improved gross margin of 64%.
• Increased full-year revenue guidance to $323 million.
• Growing adoption of Aquablation therapy among Integrated Delivery Networks (IDNs).

Negatives

• Operating expenses increased to $71.6 million.
• The company reported a net loss of $24.7 million for Q1 2025.
• Adjusted EBITDA remained negative at -$15.8 million.

Risks

• Increased operating expenses could impact future profitability.
• Potential gross margin headwind of approximately $5.0 million due to global tariff rates.
• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company projects full-year 2025 revenue to be $323.0 million, representing 44% growth over the prior year. Full-year 2025 gross margin is expected to be approximately 64.5%. Total operating expense is projected to be approximately $300.0 million, and the Adjusted EBITDA loss is expected to be ($35.0) million.

Management Comments

• Reza Zadno, Chief Executive Officer, stated that the company began 2025 with strong performance, delivering total revenue growth of 55% in the first quarter.
• He also noted that procedural momentum remained robust heading into the second quarter, reinforcing confidence that the saline disruption is behind them.
• Zadno highlighted that approximately 45% of U.S. system placements came from corporate IDN multi-unit orders, indicating that offering Aquablation therapy is becoming a long-term strategic priority for leading health systems.

Industry Context

PROCEPT BioRobotics operates in the surgical robotics market, specifically focusing on urology and BPH treatment. The company's growth reflects increasing adoption of robotic surgery and a focus on innovative solutions like Aquablation therapy. The increasing interest from Integrated Delivery Networks (IDNs) suggests a growing recognition of the value proposition of PROCEPT's technology within larger healthcare systems.

Comparison to Industry Standards

• Comparing PROCEPT BioRobotics' growth to other surgical robotics companies like Intuitive Surgical (ISRG) and Stryker (SYK) shows a competitive landscape with varying growth rates depending on the specific market segments.
• Intuitive Surgical, a leader in robotic surgery, has demonstrated consistent growth in its da Vinci system procedures, while Stryker has expanded its presence through acquisitions and product innovation.
• PROCEPT's focus on urology and BPH treatment provides a niche market with specific clinical needs, potentially allowing for faster growth compared to companies with broader surgical applications.
• The 64% gross margin is competitive with industry standards for medical device companies, but operating expenses are high due to the company's growth phase and investments in commercial expansion and R&D.

Stakeholder Impact

• Shareholders will likely react positively to the strong revenue growth and increased guidance.
• Employees may benefit from the company's expansion and growth opportunities.
• Customers (urologists and hospitals) will have access to innovative robotic solutions for BPH treatment.
• Suppliers may see increased demand for components and materials used in PROCEPT's products.

Key Dates

Keywords

PROCEPT BioRobotics, Aquablation, Revenue Guidance, Financial Results, Surgical Robotics, Urology, Robotic Systems, BPH